<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Appl Basic Med Res</journal-id><journal-id journal-id-type="iso-abbrev">Int J Appl Basic Med Res</journal-id><journal-id journal-id-type="publisher-id">IJABMR</journal-id><journal-title-group><journal-title>International Journal of Applied and Basic Medical Research</journal-title></journal-title-group><issn pub-type="ppub">2229-516X</issn><issn pub-type="epub">2248-9606</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25143884</article-id><article-id pub-id-type="pmc">4137650</article-id><article-id pub-id-type="publisher-id">IJABMR-4-95</article-id><article-id pub-id-type="doi">10.4103/2229-516X.136788</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Dexmedetomidine versus esmolol to attenuate the hemodynamic response to laryngoscopy and tracheal intubation: A randomized double-blind clinical study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reddy</surname><given-names>Siddareddigari Velayudha</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Balaji</surname><given-names>Donthu</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Shaik Nawaz</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib></contrib-group><aff id="aff1">Department of Anesthesiology and Critical Care, Rajiv Gandhi Institute of Medical Sciences, Kadapa, Andhra Pradesh, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Siddareddigari Velayudha Reddy, F-4, Teaching Quarters, Rajiv Gandhi Institute of Medical Sciences Campus, Kadapa - 516 002 Andhra Pradesh, India. E-mail: <email xlink:href="drvelayudhareddy@yahoo.co.in">drvelayudhareddy@yahoo.co.in</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Dec</season><year>2014</year></pub-date><volume>4</volume><issue>2</issue><fpage>95</fpage><lpage>100</lpage><history><date date-type="received"><day>01</day><month>4</month><year>2013</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: © International Journal of Applied and Basic Medical Research </copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3262" xml_f="3270" txt_i="11" txt_f="19">Context:</offsets></title><p><offsets xml_i="3281" xml_f="3412" txt_i="20" txt_f="151">Sympathoadrenal response to laryngoscopy and tracheal intubation manifests as transient, but distinct tachycardia and hypertension.</offsets></p></sec><sec id="st2"><title><offsets xml_i="3443" xml_f="3448" txt_i="153" txt_f="158">Aims:</offsets></title><p><offsets xml_i="3459" xml_f="3622" txt_i="159" txt_f="322">The objective of this study is to compare the clinical effects of dexmedetomidine with esmolol and control in attenuating the presser response during laryngoscopy.</offsets></p></sec><sec id="st3"><title><offsets xml_i="3653" xml_f="3673" txt_i="324" txt_f="344">Settings and Design:</offsets></title><p><offsets xml_i="3684" xml_f="3742" txt_i="345" txt_f="403">A randomized, prospective, double-blind, controlled study.</offsets></p></sec><sec id="st4"><title><offsets xml_i="3773" xml_f="3794" txt_i="405" txt_f="426">Subjects and Methods:</offsets></title><p><offsets xml_i="3805" xml_f="4034" txt_i="427" txt_f="656">We studied consented, 90 adult, American Society of Anesthesiologists physical status I and II patients of either sex, scheduled for non-cardiac surgery requiring intubation. The patients were randomly divided into three groups (</offsets><italic><offsets xml_i="4042" xml_f="4043" txt_i="656" txt_f="657">n</offsets></italic><offsets xml_i="4052" xml_f="4545" txt_i="657" txt_f="1150"> = 30). Group C received placebo, Group E received 2.0 mg/kg of esmolol and Group D received 1.0 μg/kg of dexmedetomidine, intravenously over 10 min and 3 min before induction of general anesthesia. All patients were uniformly pre-medicated, induced and intubated using thiopentone and succinylcholine as per standard protocol. Heart rate (HR), systemic arterial pressures were recorded at baseline, after study drug infusion, after induction, immediately and 3, 5, 7, 10 min after intubation.</offsets></p></sec><sec id="st5"><title><offsets xml_i="4576" xml_f="4597" txt_i="1152" txt_f="1173">Statistical Analysis:</offsets></title><p><offsets xml_i="4608" xml_f="4633" txt_i="1174" txt_f="1199">Analysis of variance and </offsets><italic><offsets xml_i="4641" xml_f="4642" txt_i="1199" txt_f="1200">t</offsets></italic><offsets xml_i="4651" xml_f="4672" txt_i="1200" txt_f="1221">-test as appropriate.</offsets></p></sec><sec id="st6"><title><offsets xml_i="4703" xml_f="4711" txt_i="1223" txt_f="1231">Results:</offsets></title><p><offsets xml_i="4722" xml_f="4808" txt_i="1232" txt_f="1318">The mean arterial pressure was significantly increased in patients receiving placebo (</offsets><italic><offsets xml_i="4816" xml_f="4817" txt_i="1318" txt_f="1319">P</offsets></italic><offsets xml_i="4826" xml_f="4853" txt_i="1319" txt_f="1343"> &lt; 0.0001) and esmolol (</offsets><italic><offsets xml_i="4861" xml_f="4862" txt_i="1343" txt_f="1344">P</offsets></italic><offsets xml_i="4871" xml_f="4961" txt_i="1344" txt_f="1431"> &lt; 0.0001) after laryngoscopy and intubation compared with baseline value and Group D (</offsets><italic><offsets xml_i="4969" xml_f="4970" txt_i="1431" txt_f="1432">P</offsets></italic><offsets xml_i="4979" xml_f="5007" txt_i="1432" txt_f="1460"> = 0.6294). The rise in HR (</offsets><italic><offsets xml_i="5015" xml_f="5016" txt_i="1460" txt_f="1461">P</offsets></italic><offsets xml_i="5025" xml_f="5064" txt_i="1461" txt_f="1500"> = 0.08481) and rate pressure product (</offsets><italic><offsets xml_i="5072" xml_f="5073" txt_i="1500" txt_f="1501">P</offsets></italic><offsets xml_i="5082" xml_f="5190" txt_i="1501" txt_f="1609"> = 0.0666) at the time of intubation were minimal and was statistically significant up to 15 min in Group D.</offsets></p></sec><sec id="st7"><title><offsets xml_i="5221" xml_f="5233" txt_i="1611" txt_f="1623">Conclusions:</offsets></title><p><offsets xml_i="5244" xml_f="5465" txt_i="1624" txt_f="1845">Both the drugs attenuated the pressure response. Of the two drugs administered, dexmedetomidine 1.0 μg/kg provides a consistent, reliable and effective attenuation of pressure responses when compared to esmolol 2.0 mg/kg.</offsets></p></sec></abstract><kwd-group><kwd>Dexmedetomidine</kwd><kwd>esmolol</kwd><kwd>hemodynamic response</kwd><kwd>intubation</kwd><kwd>laryngoscopy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5698" xml_f="5699" txt_i="1854" txt_f="1855">I</offsets><sc><offsets xml_i="5703" xml_f="5714" txt_i="1855" txt_f="1866">NTRODUCTION</offsets></sc></title><p><offsets xml_i="5730" xml_f="6267" txt_i="1867" txt_f="2404">Laryngoscopy and tracheal intubation are noxious stimuli that evoke a transient but marked sympathetic response manifesting as increase in heart rate (HR), blood pressure these changes are maximum immediately after intubation and lasts for 5-10 min, which may be well-tolerated by normal fit American Society of Anesthesiologists (ASA) 1 patients. In patients with cardiovascular disease the hemodynamic changes may lead to life threatening complications including myocardial ischemia, acute heart failure and cerebrovascular accidents.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="6300" xml_f="6301" txt_i="2404" txt_f="2405">1</offsets></xref><offsets xml_i="6308" xml_f="6537" txt_i="2405" txt_f="2634">] Treatment modalities include topical lignocaine sprays, deeper planes of anesthesia by inhalational/intravenous (IV) agents or narcotics, calcium channel blockers, vasodilators such as sodium-nitroprusside; nitroglycerine etc.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="6570" xml_f="6571" txt_i="2634" txt_f="2635">2</offsets></xref><offsets xml_i="6578" xml_f="6711" txt_i="2635" txt_f="2768">] Although there are several methods, research is still going on for attenuation of pressor response to laryngoscopy and intubation.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6744" xml_f="6745" txt_i="2768" txt_f="2769">3</offsets></xref><offsets xml_i="6752" xml_f="6825" txt_i="2769" txt_f="2842">] Esmolol is an ultra-short-acting, beta-adrenergic receptor antagonist;[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="6858" xml_f="6859" txt_i="2842" txt_f="2843">4</offsets></xref><offsets xml_i="6866" xml_f="6995" txt_i="2843" txt_f="2972">] with proven efficacy to provide hemodynamic stability during laryngoscopy and tracheal intubation without severe side-effects.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="7028" xml_f="7029" txt_i="2972" txt_f="2973">5</offsets></xref><offsets xml_i="7036" xml_f="7128" txt_i="2973" txt_f="3065">] In contrast to this, there have been a very few reports on the effects of dexmedetomidine.</offsets></p><p><offsets xml_i="7135" xml_f="7240" txt_i="3066" txt_f="3171">Dexmedetomidine is an imidazole derivative and highly selective alpha (α)-2-adrenergic receptor agonist.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="7273" xml_f="7274" txt_i="3171" txt_f="3172">6</offsets></xref><offsets xml_i="7281" xml_f="7284" txt_i="3172" txt_f="3175">] α</offsets><sub><offsets xml_i="7289" xml_f="7290" txt_i="3175" txt_f="3176">2</offsets></sub><offsets xml_i="7296" xml_f="7587" txt_i="3176" txt_f="3467"> -agonists produce hyperpolarization of noradrenergic neurons and suppression of neuronal firing in the locus cerelous leads to decreased systemic noradrenalin release results in attenuation of sympathoadrenal responses and hemodynamic stability during laryngoscopy and tracheal intubation.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="7620" xml_f="7621" txt_i="3467" txt_f="3468">7</offsets></xref><offsets xml_i="7628" xml_f="7830" txt_i="3468" txt_f="3670">] The topic of study was selected because tachycardia and hypertension may get further enhanced in response, to laryngoscope and tracheal intubation, proven dangerous to cardiovascular disease patients.</offsets></p><p><offsets xml_i="7837" xml_f="8102" txt_i="3671" txt_f="3936">In a randomized, prospective, double-blind, controlled study, we compare the safety and efficacy of single bolus IV dose of dexmedetomidine with single bolus IV dose of esmolol and placebo in attenuating hemodynamic response to laryngoscopy and tracheal intubation.</offsets></p></sec><sec sec-type="methods" id="sec1-2"><title><offsets xml_i="8155" xml_f="8156" txt_i="3938" txt_f="3939">S</offsets><sc><offsets xml_i="8160" xml_f="8171" txt_i="3939" txt_f="3950">UBJECTS AND</offsets></sc><offsets xml_i="8176" xml_f="8178" txt_i="3950" txt_f="3952"> M</offsets><sc><offsets xml_i="8182" xml_f="8188" txt_i="3952" txt_f="3958">ETHODS</offsets></sc></title><p><offsets xml_i="8204" xml_f="9118" txt_i="3959" txt_f="4873">After approval of the study protocol by the Institutional Ethical Committee, written informed consent was obtained from each patient. 90 normotensive, ASA physical status I and II patients of either sex, aged 40-60 years, who were scheduled for elective non-cardiac surgery under general anesthesia (GA) requiring endotracheal (ET) intubation, were included in this study. All patients were thoroughly examined and routine investigations were carried out. The patients who refuse to consent, patients whose physical characteristics suggested difficulties in intubation (Mallampati grades III and IV), who had hypertension or cardiovascular, respiratory, neurological, psychological, hepatic, endocrinal, renal disease and taking any medication (e.g. opioids or sedatives in the week prior to surgery), having history of alcohol abuse or drug allergies, pregnant and lactating patients were excluded from the study.</offsets></p><p><offsets xml_i="9125" xml_f="10148" txt_i="4874" txt_f="5897">Baseline (average of three readings) vital parameters of patients’ including HR, systolic arterial pressure (SAP), diastolic arterial pressure (DAP); mean arterial pressure (MAP) and oxygen saturation were recorded in the pre-operative ward. After 1 h patients were taken to the operation theatre. In the operating room an IV line was secured with 18-G venous cannula and Ringer's lactate infusion (6 ml/kg) was started. Routine standard monitors such as pulse oxymetry, electrocardiography (ECG) and non-invasive blood pressure were applied and monitoring started. All the patients were uniformly pre-medicated with IV ondansetron 0.08 mg/kg and glycopyrrolate 0.004 mg/kg, 10 min before induction. The study drugs were premixed to a volume of 10 ml and were presented as coded syringes by an anesthesiologist who is not involved in the study. The patients were blinded to the treatment group and all recordings were performed by an anesthesiologist blinded to the group allocation, thus the study was made double-blinded.</offsets></p><p><offsets xml_i="10155" xml_f="11314" txt_i="5898" txt_f="7057">The patients were randomly divided into three equal groups of 30 each (Balanced randomization using a computer program, block size 10). The patients in control Group C received 10 ml of physiologic saline, Group E received esmolol 2.0 mg/kg and Group D received dexmedetomidine 1.0 μg/kg as slow IV infusion over a period of 10 min. The patient's HR and blood pressure were stabilized and pre-oxygenated for 3 min after study drug infusion. Then the induction of anesthesia was performed with thiopentone 5.0 mg/kg and then succinylcholine 2.0 mg/kg was administered IV as per standard protocol. The patient's lungs were ventilated manually with 100% oxygen. Laryngoscopy was attempted 90 s after the administration of succinylcholine with Macintosh curved blade number 4 by an anesthesiologist having more than 9 years of experience. The trachea was intubated with appropriate size-cuffed disposable ET tube. Laryngoscopy and intubation was limited to 15-20 s in all patients, failure to intubate within this period was excluded from this study. After confirming the position and fixing the ET tube with adhesive plaster anesthesia was maintained with, 66% N</offsets><sub><offsets xml_i="11319" xml_f="11320" txt_i="7057" txt_f="7058">2</offsets></sub><offsets xml_i="11326" xml_f="11953" txt_i="7058" txt_f="7685">O in 33% oxygen and 1% sevoflurane in 6 l of fresh gas flow. Bolus IV dose of 0.08 mg/kg followed by intermittent dose of 0.02 mg/kg vecuronium was used for muscle relaxation. At the end of the surgery all patients were reversed with neostigmine 0.05 mg/kg and glycopyrrolate 0.008 mg/kg IV. Patients were extubated after adequate recovery and then shifted to anesthesia recovery room and monitored for complications such as pain, respiratory depression; hypertension, hypotension, bradycardia, drowsiness, rigidity, nausea or vomiting and attended appropriately, rescue treatment was also noted during anesthesia and recovery.</offsets></p><p><offsets xml_i="11960" xml_f="12612" txt_i="7686" txt_f="8335">Vital parameters such as HR, SAP, DAP and MAP were recorded, at baseline, after study drug infusion, after induction, immediately and 3, 5, 7 and 10 min after intubation and every 5 min there after using multipara monitor. No surgical intervention was allowed throughout the study period of 10 min. The hemodynamic alterations like a decrease in MAP greater than 20% below the baseline value or SAP less than 90 mm of Hg was treated with primarily by increasing the IV fluid infusion rate and then reducing sevoflurane concentration or incremental doses of ephedrine 4 mg bolus IV. Decrease in HR (&lt;50 beats/min) was treated with atropine 0.5 mg IV.</offsets></p><sec id="sec2-1"><title><offsets xml_i="12640" xml_f="12660" txt_i="8336" txt_f="8356">Statistical analysis</offsets></title><p><offsets xml_i="12671" xml_f="13285" txt_i="8357" txt_f="8971">After the initial pilot observations, it was decided that a 20% of difference should be the minimum detectable difference of means in all groups. The standard deviation (SD) of residual was also kept same (20% of average difference between the groups). The α value was 0.05 and the power (1-a) of the study was 0.80. Thus, the calculated sample size for each group was 23 patients. Preserving the designing effect it was decided to include 30 patients in each group. Groups were compared for demographic data (age, weight) and hemodynamic parameters (HR, blood pressure) by one way analysis of variance and paired </offsets><italic><offsets xml_i="13293" xml_f="13294" txt_i="8971" txt_f="8972">t</offsets></italic><offsets xml_i="13303" xml_f="13399" txt_i="8972" txt_f="9068">-test was used for comparison among the groups, while for comparison within the groups unpaired </offsets><italic><offsets xml_i="13407" xml_f="13408" txt_i="9068" txt_f="9069">t</offsets></italic><offsets xml_i="13417" xml_f="13533" txt_i="9069" txt_f="9185">-test was used. Probability was considered to be significant if less than 0.05. Data are represented as mean and SD.</offsets></p></sec></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="13592" xml_f="13593" txt_i="9188" txt_f="9189">R</offsets><sc><offsets xml_i="13597" xml_f="13603" txt_i="9189" txt_f="9195">ESULTS</offsets></sc></title><p><offsets xml_i="13619" xml_f="13911" txt_i="9196" txt_f="9488">All Cases were selected from general surgery only; all the 90 patients completed the study. The demographic profile of the patients in terms of age, body weight, male:female ratio, ASA status, Mallampati Class were comparable and there were no significant differences among the three groups (</offsets><italic><offsets xml_i="13919" xml_f="13920" txt_i="9488" txt_f="9489">P</offsets></italic><offsets xml_i="13929" xml_f="13942" txt_i="9489" txt_f="9499"> &gt; 0.05) [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="13974" xml_f="13981" txt_i="9499" txt_f="9506">Table 1</offsets></xref><offsets xml_i="13988" xml_f="13990" txt_i="9506" txt_f="9508">].</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="14038" xml_f="14045" txt_i="9509" txt_f="9516">Table 1</offsets></label><caption><p><offsets xml_i="14065" xml_f="14090" txt_i="9516" txt_f="9541">Patient's characteristics</offsets></p></caption><graphic xlink:href="IJABMR-4-95-g001"></graphic></table-wrap><p><offsets xml_i="14169" xml_f="14305" txt_i="9542" txt_f="9678">The increase in mean HR after intubation was seen in all the three groups. But the mean increase was minimal 5.83% in Group D (4 beats, </offsets><italic><offsets xml_i="14313" xml_f="14314" txt_i="9678" txt_f="9679">P</offsets></italic><offsets xml_i="14323" xml_f="14378" txt_i="9679" txt_f="9734"> = 0.0848), when compared with Group E 14% (9.81beats; </offsets><italic><offsets xml_i="14386" xml_f="14387" txt_i="9734" txt_f="9735">P</offsets></italic><offsets xml_i="14396" xml_f="14436" txt_i="9735" txt_f="9775"> = 0.0152) and Group C 30% (24.9 beats; </offsets><italic><offsets xml_i="14444" xml_f="14445" txt_i="9775" txt_f="9776">P</offsets></italic><offsets xml_i="14454" xml_f="14499" txt_i="9776" txt_f="9818"> &lt; 0.0001), which was highly significant (</offsets><italic><offsets xml_i="14507" xml_f="14508" txt_i="9818" txt_f="9819">P</offsets></italic><offsets xml_i="14517" xml_f="14617" txt_i="9819" txt_f="9916"> &lt; 0.0001). Also, only in the Group D, there was no significant rise of HR at any time interval [</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="14647" xml_f="14655" txt_i="9916" txt_f="9924">Figure 1</offsets></xref><offsets xml_i="14662" xml_f="14664" txt_i="9924" txt_f="9926">].</offsets></p><fig id="F1" position="float"><label><offsets xml_i="14705" xml_f="14713" txt_i="9927" txt_f="9935">Figure 1</offsets></label><caption><p><offsets xml_i="14733" xml_f="14774" txt_i="9935" txt_f="9976">Mean heart rate of patients in Groups C-D</offsets></p></caption><graphic xlink:href="IJABMR-4-95-g002"></graphic></fig><p><offsets xml_i="14846" xml_f="14952" txt_i="9977" txt_f="10083">The mean SAP levels in Group D were significantly lower than Groups C and E immediately after intubation (</offsets><italic><offsets xml_i="14960" xml_f="14961" txt_i="10083" txt_f="10084">P</offsets></italic><offsets xml_i="14970" xml_f="14983" txt_i="10084" txt_f="10094"> &lt; 0.001, </offsets><italic><offsets xml_i="14991" xml_f="14992" txt_i="10094" txt_f="10095">P</offsets></italic><offsets xml_i="15001" xml_f="15161" txt_i="10095" txt_f="10252"> &gt; 0.001 respectively) and until the end of surgery. Esmolol does not prevented the raise in SAP following intubation, but the raise was significantly less (</offsets><italic><offsets xml_i="15169" xml_f="15170" txt_i="10252" txt_f="10253">P</offsets></italic><offsets xml_i="15179" xml_f="15254" txt_i="10253" txt_f="10328"> = 0.0269) when compared with the patients who does not received any drug [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="15286" xml_f="15293" txt_i="10328" txt_f="10335">Table 2</offsets></xref><offsets xml_i="15300" xml_f="15302" txt_i="10335" txt_f="10337">].</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="15350" xml_f="15357" txt_i="10338" txt_f="10345">Table 2</offsets></label><caption><p><offsets xml_i="15377" xml_f="15425" txt_i="10345" txt_f="10393">Comparison of SAP (mm of Hg) in the three groups</offsets></p></caption><graphic xlink:href="IJABMR-4-95-g003"></graphic></table-wrap><p><offsets xml_i="15504" xml_f="15700" txt_i="10394" txt_f="10590">The DAP levels in Group D were significantly lower than Groups C and E at all times after intubation. In esmolol group, there is a transient raise 21.4% (16.63 mm Hg) in DAP following intubation (</offsets><italic><offsets xml_i="15708" xml_f="15709" txt_i="10590" txt_f="10591">P</offsets></italic><offsets xml_i="15718" xml_f="15785" txt_i="10591" txt_f="10655"> &lt; 0.0001) at other times it remained below the baseline level [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="15817" xml_f="15824" txt_i="10655" txt_f="10662">Table 3</offsets></xref><offsets xml_i="15831" xml_f="15833" txt_i="10662" txt_f="10664">].</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="15881" xml_f="15888" txt_i="10665" txt_f="10672">Table 3</offsets></label><caption><p><offsets xml_i="15908" xml_f="15980" txt_i="10672" txt_f="10744">Comparison of diastolic arterial pressure (mm of Hg) in the three groups</offsets></p></caption><graphic xlink:href="IJABMR-4-95-g004"></graphic></table-wrap><p><offsets xml_i="16059" xml_f="16198" txt_i="10745" txt_f="10884">The MAP was comparable in all the three groups at baseline level. The MAP decreased following induction, which was significant in Group C (</offsets><italic><offsets xml_i="16206" xml_f="16207" txt_i="10884" txt_f="10885">P</offsets></italic><offsets xml_i="16216" xml_f="16258" txt_i="10885" txt_f="10927"> = 0.024) but not significant in Group E (</offsets><italic><offsets xml_i="16266" xml_f="16267" txt_i="10927" txt_f="10928">P</offsets></italic><offsets xml_i="16276" xml_f="16299" txt_i="10928" txt_f="10951"> = 0.088) and Group D (</offsets><italic><offsets xml_i="16307" xml_f="16308" txt_i="10951" txt_f="10952">P</offsets></italic><offsets xml_i="16317" xml_f="16523" txt_i="10952" txt_f="11158"> = 0.3145). The MAP rose by 30% (28.04 mm Hg) in Group C, 26% (24.00 mm Hg) in Group E and only 2% (1.67 mm Hg) in Group D at intubation. The rise in MAP was highly significant after intubation in Group C (</offsets><italic><offsets xml_i="16531" xml_f="16532" txt_i="11158" txt_f="11159">P</offsets></italic><offsets xml_i="16541" xml_f="16583" txt_i="11159" txt_f="11198"> &lt; 0.0001) and significant in Group E (</offsets><italic><offsets xml_i="16591" xml_f="16592" txt_i="11198" txt_f="11199">P</offsets></italic><offsets xml_i="16601" xml_f="16651" txt_i="11199" txt_f="11246"> &lt; 0.05) which was not significant in Group D (</offsets><italic><offsets xml_i="16659" xml_f="16660" txt_i="11246" txt_f="11247">P</offsets></italic><offsets xml_i="16669" xml_f="16682" txt_i="11247" txt_f="11257"> &gt; 0.05) [</offsets><xref ref-type="table" rid="T4"><offsets xml_i="16714" xml_f="16721" txt_i="11257" txt_f="11264">Table 4</offsets></xref><offsets xml_i="16728" xml_f="16730" txt_i="11264" txt_f="11266">].</offsets></p><table-wrap id="T4" position="float"><label><offsets xml_i="16778" xml_f="16785" txt_i="11267" txt_f="11274">Table 4</offsets></label><caption><p><offsets xml_i="16805" xml_f="16868" txt_i="11274" txt_f="11337">Comparison mean arterial pressure (mm Hg) level in three groups</offsets></p></caption><graphic xlink:href="IJABMR-4-95-g005"></graphic></table-wrap><p><offsets xml_i="16947" xml_f="17138" txt_i="11338" txt_f="11529">The rate pressure product (RPP) was calculated as the product of HR and SAP (RPP = HR × SAP). In our study the RPP during intubation revealed a highly significant increase in Group C (76.5%, </offsets><italic><offsets xml_i="17146" xml_f="17147" txt_i="11529" txt_f="11530">P</offsets></italic><offsets xml_i="17156" xml_f="17212" txt_i="11530" txt_f="11583"> &lt; 0.0001) and significant increase in Group E (49%, </offsets><italic><offsets xml_i="17220" xml_f="17221" txt_i="11583" txt_f="11584">P</offsets></italic><offsets xml_i="17230" xml_f="17300" txt_i="11584" txt_f="11651"> &lt; 0.001), whereas the increase was insignificant in Group D (16%, </offsets><italic><offsets xml_i="17308" xml_f="17309" txt_i="11651" txt_f="11652">P</offsets></italic><offsets xml_i="17318" xml_f="17497" txt_i="11652" txt_f="11828"> &gt; 0.0666). These changes were highly significant up to 15 min post-intubation. Although comparing Group E to Group D the increase in RPP in Group E at the time of intubation (</offsets><italic><offsets xml_i="17505" xml_f="17506" txt_i="11828" txt_f="11829">P</offsets></italic><offsets xml_i="17515" xml_f="17625" txt_i="11829" txt_f="11936"> &lt; 0.001) was statistically significant. The rise in mean RPP was least in Group D and highest in Group C [</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="17655" xml_f="17663" txt_i="11936" txt_f="11944">Figure 2</offsets></xref><offsets xml_i="17670" xml_f="17672" txt_i="11944" txt_f="11946">].</offsets></p><fig id="F2" position="float"><label><offsets xml_i="17713" xml_f="17721" txt_i="11947" txt_f="11955">Figure 2</offsets></label><caption><p><offsets xml_i="17741" xml_f="17817" txt_i="11955" txt_f="12031">The comprehensive changes in rate pressure product of patients in Groups C-D</offsets></p></caption><graphic xlink:href="IJABMR-4-95-g006"></graphic></fig></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="17938" xml_f="17939" txt_i="12033" txt_f="12034">D</offsets><sc><offsets xml_i="17943" xml_f="17952" txt_i="12034" txt_f="12043">ISCUSSION</offsets></sc></title><p><offsets xml_i="17968" xml_f="18282" txt_i="12044" txt_f="12358">In this study infusion of dexmedetomidine 1.0 μg/kg prior to induction of anesthesia suppressed the hemodynamic response to tracheal intubation in normotensive patients. This suppression in cardiovascular responses was found to be greater with dexmedetomidine than that resulted from infusion of esmolol 2.0 mg/kg.</offsets></p><p><offsets xml_i="18289" xml_f="18576" txt_i="12359" txt_f="12646">Tachycardia and hypertension are more common following laryngoscope and ET intubation. Prophylaxis include topical lignocaine sprays, deeper planes of anesthesia by inhalational agents; narcotics, calcium channel blockers, vasodilators such as sodium-nitroprusside; nitroglycerine etc.,[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="18609" xml_f="18610" txt_i="12646" txt_f="12647">2</offsets></xref><offsets xml_i="18617" xml_f="18919" txt_i="12647" txt_f="12949">] but they have got side-effects such as sedation, respiratory depression, hypotension and bradycardia. Dexmedetomidine has sedative, anxiolytic, analgesic and sympatholytic, effects may blunt the cardiovascular responses in the peri-operative period without causing significant respiratory depression.</offsets></p><p><offsets xml_i="18926" xml_f="19181" txt_i="12950" txt_f="13205">Among the β-adrenergic blocking drugs, esmolol seems to be an appropriate selection for attenuating the hemodynamic response to laryngoscopy and tracheal intubation, because of its cardioselectivity, rapid onset of action and short elimination half-life.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="19214" xml_f="19215" txt_i="13205" txt_f="13206">8</offsets></xref><offsets xml_i="19222" xml_f="19397" txt_i="13206" txt_f="13381">] There have been several reports discussing the effects of esmolol on both HR and arterial blood pressure during laryngoscopy and ET intubation compared with placebo. Miller </offsets><italic><offsets xml_i="19405" xml_f="19410" txt_i="13381" txt_f="13386">et al</offsets></italic><offsets xml_i="19419" xml_f="19421" txt_i="13386" txt_f="13388">.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="19454" xml_f="19455" txt_i="13388" txt_f="13389">9</offsets></xref><offsets xml_i="19462" xml_f="19652" txt_i="13389" txt_f="13579">] in their study have reported that 100 mg of single bolus dose of esmolol was effective for controlling the hemodynamic response to tracheal intubation in a Canadian multicenter trial. Liu </offsets><italic><offsets xml_i="19660" xml_f="19665" txt_i="13579" txt_f="13584">et al</offsets></italic><offsets xml_i="19674" xml_f="19934" txt_i="13584" txt_f="13844">. who used esmolol infusion to control hemodynamic responses associated with intubation, found significant decreases in HR and SAP prior to induction and post-intubation, the increase was 50% less in the esmolol-treated patients compared to the placebo group.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="19968" xml_f="19970" txt_i="13844" txt_f="13846">10</offsets></xref><offsets xml_i="19977" xml_f="19978" txt_i="13846" txt_f="13847">]</offsets></p><p><offsets xml_i="19985" xml_f="20390" txt_i="13848" txt_f="14253">Esmolol decreases the force of contraction and HR by blocking beta-adrenergic receptors of the sympathetic nervous system which are found in the heart, blood vessels and other organs of the body. Esmolol prevents the action of two naturally occurring neurotransmitters epinephrine and nor-epinephrine, there by attenuates the tachycardia and hypertensive responses to laryngoscopy and tracheal intubation.</offsets></p><p><offsets xml_i="20397" xml_f="20532" txt_i="14254" txt_f="14389">Although esmolol is considered to have significant effect on both tachycardia and hypertensive response following ET intubation, Oxorn </offsets><italic><offsets xml_i="20540" xml_f="20545" txt_i="14389" txt_f="14394">et al</offsets></italic><offsets xml_i="20554" xml_f="20556" txt_i="14394" txt_f="14396">.[</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="20590" xml_f="20592" txt_i="14396" txt_f="14398">11</offsets></xref><offsets xml_i="20599" xml_f="20734" txt_i="14398" txt_f="14533">] concluded that esmolol in bolus doses of 100 mg and 200 mg affects solely the chronotropic response in a significant manner. Kindler </offsets><italic><offsets xml_i="20742" xml_f="20747" txt_i="14533" txt_f="14538">et al</offsets></italic><offsets xml_i="20756" xml_f="20885" txt_i="14538" txt_f="14667">. found that esmolol administration before laryngoscopy was sufficient to control HR after intubation but it did not affect SAP.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="20919" xml_f="20921" txt_i="14667" txt_f="14669">12</offsets></xref><offsets xml_i="20928" xml_f="21337" txt_i="14669" txt_f="15078">] Similarly, in this study, esmolol was not as effective on attenuating the hypertensive response as it was on attenuating the chronotropic response to tracheal intubation. In fact, a significant increase in SAP and a transient raise in DAP was observed after intubation compared to the baseline values and when compared with dexmedetomidine the increase in SAP was greater and more significant in this study.</offsets></p><p><offsets xml_i="21344" xml_f="21359" txt_i="15079" txt_f="15094">Direct acting α</offsets><sub><offsets xml_i="21364" xml_f="21365" txt_i="15094" txt_f="15095">2</offsets></sub><offsets xml_i="21371" xml_f="21594" txt_i="15095" txt_f="15318"> -adrenoceptor agonists represent clinically significant effects on the anesthetic requirements and on the sympathoadrenal and hemodynamic responses induced by anesthesia including tracheal intubation and surgery. Scheinin </offsets><italic><offsets xml_i="21602" xml_f="21607" txt_i="15318" txt_f="15323">et al</offsets></italic><offsets xml_i="21616" xml_f="21618" txt_i="15323" txt_f="15325">.[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="21652" xml_f="21654" txt_i="15325" txt_f="15327">13</offsets></xref><offsets xml_i="21661" xml_f="21821" txt_i="15327" txt_f="15487">] reported that 0.6 μg/kg dexmedetomidine decreased, but not totally suppressed, the hemodynamic response to tracheal intubation in healthy individuals. Keniya </offsets><italic><offsets xml_i="21829" xml_f="21834" txt_i="15487" txt_f="15492">et al</offsets></italic><offsets xml_i="21843" xml_f="22025" txt_i="15492" txt_f="15674">. stated that the pre-treatment with dexmedetomidine 1.0 μg/kg attenuated, but not totally obtunded the cardiovascular response to tracheal intubation after induction of anesthesia.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="22059" xml_f="22061" txt_i="15674" txt_f="15676">14</offsets></xref><offsets xml_i="22068" xml_f="22714" txt_i="15676" txt_f="16322">] In this study, we did not observed any significant differences in HR and arterial blood pressure values between the baseline and post-intubation values in the dexmedetomidine group. Similar to the two studies mentioned above, the mean percentage variation analysis at the stated moments revealed an absence of any increase in HR, SAP and DAP in dexmedetomidine group suggesting dexmedetomidine as an effective agent for blunting the hemodynamic response to laryngoscopy and tracheal intubation. Bradycardia and hypotension have been reported in studies pertaining to the effect of dexmedetomidine administration on peri-operative hemodynamics.[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="22748" xml_f="22750" txt_i="16322" txt_f="16324">15</offsets></xref><xref rid="ref16" ref-type="bibr"><offsets xml_i="22791" xml_f="22793" txt_i="16324" txt_f="16326">16</offsets></xref><xref rid="ref17" ref-type="bibr"><offsets xml_i="22834" xml_f="22836" txt_i="16326" txt_f="16328">17</offsets></xref><offsets xml_i="22843" xml_f="22894" txt_i="16328" txt_f="16379">] In contrast to the previously mentioned studies,[</offsets><xref rid="ref16" ref-type="bibr"><offsets xml_i="22928" xml_f="22930" txt_i="16379" txt_f="16381">16</offsets></xref><xref rid="ref18" ref-type="bibr"><offsets xml_i="22971" xml_f="22973" txt_i="16381" txt_f="16383">18</offsets></xref><xref rid="ref19" ref-type="bibr"><offsets xml_i="23014" xml_f="23016" txt_i="16383" txt_f="16385">19</offsets></xref><offsets xml_i="23023" xml_f="23696" txt_i="16385" txt_f="17058">] we did not detected any excessive reduction in HR or systemic blood pressure values in the dexmedetomidine group compared with other groups. Moreover, in this study neither bradycardia nor hypotension was observed in the patients. Dexmedetomidine has been used IV in doses ranging from 0.1 to 10 μg/kg/h but higher doses have been associated with a significant increase in incidence of bradycardia and hypotension. Rapid administration of dexmedetomidine might produce tachycardia, bradycardia and hypertension followed by hypotension. We administered dexmedetomidine, 1.0 μg/kg slowly, over 10 min in our study hence no bradycardia or hypotension was found in our study.</offsets></p><p><offsets xml_i="23703" xml_f="23808" txt_i="17059" txt_f="17164">The α-adrenoceptors are involved in regulating the autonomic nervous system and cardiovascular systems. α</offsets><sub><offsets xml_i="23813" xml_f="23814" txt_i="17164" txt_f="17165">2</offsets></sub><offsets xml_i="23820" xml_f="24003" txt_i="17165" txt_f="17348"> -adrenoceptors are located on blood vessels, where they mediate vasoconstriction and on sympathetic presynaptic terminals where they inhibit epinephrine and nor-epinephrine release.[</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="24037" xml_f="24039" txt_i="17348" txt_f="17350">20</offsets></xref><offsets xml_i="24046" xml_f="24049" txt_i="17350" txt_f="17353">] α</offsets><sub><offsets xml_i="24054" xml_f="24055" txt_i="17353" txt_f="17354">2</offsets></sub><offsets xml_i="24061" xml_f="24326" txt_i="17354" txt_f="17619"> -adrenoceptors are also located within the central nervous system and their activation leads to sedation, a reduction of tonic levels of sympathetic outflow and an augmentation of Vagal activity. This can result in a decrease in HR and cardiac output. The use of α</offsets><sub><offsets xml_i="24331" xml_f="24332" txt_i="17619" txt_f="17620">2</offsets></sub><offsets xml_i="24338" xml_f="24503" txt_i="17620" txt_f="17785"> -agonists in the peri-operative period has been associated with reduced anesthetic requirements and attenuated HR and blood pressure responses to stressful events.[</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="24537" xml_f="24539" txt_i="17785" txt_f="17787">21</offsets></xref><xref rid="ref22" ref-type="bibr"><offsets xml_i="24580" xml_f="24582" txt_i="17787" txt_f="17789">22</offsets></xref><offsets xml_i="24589" xml_f="24590" txt_i="17789" txt_f="17790">]</offsets></p><p><offsets xml_i="24597" xml_f="24877" txt_i="17791" txt_f="18071">Monitoring of HR and ECG has shown no evidence of myocardial insult in any of the patients in any group in our study. It is advisable and safe to use dexmedetomidine in patients to attenuate the hemodynamic responses of cardiovascular system during laryngoscopy and ET intubation.</offsets></p></sec><sec sec-type="conclusions" id="sec1-5"><title><offsets xml_i="24934" xml_f="24935" txt_i="18073" txt_f="18074">C</offsets><sc><offsets xml_i="24939" xml_f="24948" txt_i="18074" txt_f="18083">ONCLUSION</offsets></sc></title><p><offsets xml_i="24964" xml_f="25379" txt_i="18084" txt_f="18499">Evaluation of baseline and immediately after intubation values, revealed a greater percentage variation in MAP in the esmolol and control groups as compared to the dexmedetomidine group. Therefore, within the constraints of this study we demonstrated that administration of a single dose of dexmedetomidine before GA induction was an effective method for attenuating the hemodynamic response to tracheal intubation.</offsets></p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nill.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shribman</surname><given-names>AJ</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Achola</surname><given-names>KJ</given-names></name></person-group><article-title>Cardiovascular and catecholamine responses to laryngoscopy with and without tracheal intubation</article-title><source>Br J Anaesth</source><year>1987</year><volume>59</volume><fpage>295</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">3828177</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovac</surname><given-names>AL</given-names></name></person-group><article-title>Controlling the hemodynamic response to laryngoscopy and endotracheal intubation</article-title><source>J Clin Anesth</source><year>1996</year><volume>8</volume><fpage>63</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">8695083</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva Neto</surname><given-names>WV</given-names></name><name><surname>Azevedo</surname><given-names>GS</given-names></name><name><surname>Coelho</surname><given-names>FO</given-names></name><name><surname>Netto</surname><given-names>EM</given-names></name><name><surname>Ladeia</surname><given-names>AM</given-names></name></person-group><article-title>Evaluation of hemodynamic variations during anesthetic induction in treated hypertensive patients</article-title><source>Rev Bras Anestesiol</source><year>2008</year><volume>58</volume><fpage>330</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">19378581</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghause</surname><given-names>MS</given-names></name><name><surname>Singh</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Wahal</surname><given-names>R</given-names></name><name><surname>Bhatia</surname><given-names>VK</given-names></name><name><surname>Agarwal</surname><given-names>J</given-names></name></person-group><article-title>A study of cardiovascular response during laryngoscopy and intubation and their attenuation by ultra short acting b-blocker esmolol</article-title><source>Indian J Anaesth</source><year>2002</year><volume>46</volume><fpage>104</fpage><lpage>6</lpage></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louizos</surname><given-names>AA</given-names></name><name><surname>Hadzilia</surname><given-names>SJ</given-names></name><name><surname>Davilis</surname><given-names>DI</given-names></name><name><surname>Samanta</surname><given-names>EG</given-names></name><name><surname>Georgiou</surname><given-names>LG</given-names></name></person-group><article-title>Administration of esmolol in microlaryngeal surgery for blunting the hemodynamic response during laryngoscopy and tracheal intubation in cigarette smokers</article-title><source>Ann Otol Rhinol Laryngol</source><year>2007</year><volume>116</volume><fpage>107</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">17388233</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>ZP</given-names></name><name><surname>Ferguson</surname><given-names>CN</given-names></name><name><surname>Jones</surname><given-names>RM</given-names></name></person-group><article-title>Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role</article-title><source>Anaesthesia</source><year>1999</year><volume>54</volume><fpage>146</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">10215710</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grewal</surname><given-names>A</given-names></name></person-group><article-title>Dexmedetomidine: New avenues</article-title><source>J Anaesthesiol Clin Pharmacol</source><year>2011</year><volume>27</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">21897496</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sum</surname><given-names>CY</given-names></name><name><surname>Yacobi</surname><given-names>A</given-names></name><name><surname>Kartzinel</surname><given-names>R</given-names></name><name><surname>Stampfli</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>CS</given-names></name><name><surname>Lai</surname><given-names>CM</given-names></name></person-group><article-title>Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite</article-title><source>Clin Pharmacol Ther</source><year>1983</year><volume>34</volume><fpage>427</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">6617063</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DR</given-names></name><name><surname>Martineau</surname><given-names>RJ</given-names></name><name><surname>Wynands</surname><given-names>JE</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name></person-group><article-title>Bolus administration of esmolol for controlling the haemodynamic response to tracheal intubation: The Canadian Multicentre Trial</article-title><source>Can J Anaesth</source><year>1991</year><volume>38</volume><fpage>849</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">1683818</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>PL</given-names></name><name><surname>Gatt</surname><given-names>S</given-names></name><name><surname>Gugino</surname><given-names>LD</given-names></name><name><surname>Mallampati</surname><given-names>SR</given-names></name><name><surname>Covino</surname><given-names>BG</given-names></name></person-group><article-title>Esmolol for control of increases in heart rate and blood pressure during tracheal intubation after thiopentone and succinylcholine</article-title><source>Can Anaesth Soc J</source><year></year><volume>33</volume><fpage>556</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">3768764</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oxorn</surname><given-names>D</given-names></name><name><surname>Knox</surname><given-names>JW</given-names></name><name><surname>Hill</surname><given-names>J</given-names></name></person-group><article-title>Bolus doses of esmolol for the prevention of perioperative hypertension and tachycardia</article-title><source>Can J Anaesth</source><year>1990</year><volume>37</volume><fpage>206</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1968784</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindler</surname><given-names>CH</given-names></name><name><surname>Schumacher</surname><given-names>PG</given-names></name><name><surname>Schneider</surname><given-names>MC</given-names></name><name><surname>Urwyler</surname><given-names>A</given-names></name></person-group><article-title>Effects of intravenous lidocaine and/or esmolol on hemodynamic responses to laryngoscopy and intubation: A double-blind, controlled clinical trial</article-title><source>J Clin Anesth</source><year>1996</year><volume>8</volume><fpage>491</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8872690</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheinin</surname><given-names>B</given-names></name><name><surname>Lindgren</surname><given-names>L</given-names></name><name><surname>Randell</surname><given-names>T</given-names></name><name><surname>Scheinin</surname><given-names>H</given-names></name><name><surname>Scheinin</surname><given-names>M</given-names></name></person-group><article-title>Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and peroperative fentanyl</article-title><source>Br J Anaesth</source><year>1992</year><volume>68</volume><fpage>126</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">1347229</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keniya</surname><given-names>VM</given-names></name><name><surname>Ladi</surname><given-names>S</given-names></name><name><surname>Naphade</surname><given-names>R</given-names></name></person-group><article-title>Dexmedetomidine attenuates sympathoadrenal response to tracheal intubation and reduces perioperative anaesthetic requirement</article-title><source>Indian J Anaesth</source><year>2011</year><volume>55</volume><fpage>352</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22013250</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Abraham</surname><given-names>R</given-names></name><name><surname>Ogorek</surname><given-names>D</given-names></name><name><surname>Weinbroum</surname><given-names>AA</given-names></name></person-group><article-title>Dexmedetomidine: A promising agent for anesthesia and perioperative care</article-title><source>Isr Med Assoc J</source><year>2000</year><volume>2</volume><fpage>793</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11344741</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>CJ</given-names></name><name><surname>De Lange</surname><given-names>S</given-names></name></person-group><article-title>Effects of a single pre-operative dexmedetomidine dose on isoflurane requirements and peri-operative haemodynamic stability</article-title><source>Anaesthesia</source><year>1997</year><volume>52</volume><fpage>736</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">9291757</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erkola</surname><given-names>O</given-names></name><name><surname>Korttila</surname><given-names>K</given-names></name><name><surname>Aho</surname><given-names>M</given-names></name><name><surname>Haasio</surname><given-names>J</given-names></name><name><surname>Aantaa</surname><given-names>R</given-names></name><name><surname>Kallio</surname><given-names>A</given-names></name></person-group><article-title>Comparison of intramuscular dexmedetomidine and midazolam premedication for elective abdominal hysterectomy</article-title><source>Anesth Analg</source><year>1994</year><volume>79</volume><fpage>646</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">7943770</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheinin</surname><given-names>H</given-names></name><name><surname>Jaakola</surname><given-names>ML</given-names></name><name><surname>Sjövall</surname><given-names>S</given-names></name><name><surname>Ali-Melkkilä</surname><given-names>T</given-names></name><name><surname>Kaukinen</surname><given-names>S</given-names></name><name><surname>Turunen</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Intramuscular dexmedetomidine as premedication for general anesthesia. A comparative multicenter study</article-title><source>Anesthesiology</source><year>1993</year><volume>78</volume><fpage>1065</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">8512099</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aantaa</surname><given-names>RE</given-names></name><name><surname>Kanto</surname><given-names>JH</given-names></name><name><surname>Scheinin</surname><given-names>M</given-names></name><name><surname>Kallio</surname><given-names>AM</given-names></name><name><surname>Scheinin</surname><given-names>H</given-names></name></person-group><article-title>Dexmedetomidine premedication for minor gynecologic surgery</article-title><source>Anesth Analg</source><year>1990</year><volume>70</volume><fpage>407</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">1969252</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yildiz</surname><given-names>M</given-names></name><name><surname>Tavlan</surname><given-names>A</given-names></name><name><surname>Tuncer</surname><given-names>S</given-names></name><name><surname>Reisli</surname><given-names>R</given-names></name><name><surname>Yosunkaya</surname><given-names>A</given-names></name><name><surname>Otelcioglu</surname><given-names>S</given-names></name></person-group><article-title>Effect of dexmedetomidine on haemodynamic responses to laryngoscopy and intubation: Perioperative haemodynamics and anaesthetic requirements</article-title><source>Drugs R D</source><year>2006</year><volume>7</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">16620136</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloor</surname><given-names>BC</given-names></name><name><surname>Ward</surname><given-names>DS</given-names></name><name><surname>Belleville</surname><given-names>JP</given-names></name><name><surname>Maze</surname><given-names>M</given-names></name></person-group><article-title>Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes</article-title><source>Anesthesiology</source><year>1992</year><volume>77</volume><fpage>1134</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">1361311</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>TJ</given-names></name><name><surname>Hall</surname><given-names>JE</given-names></name><name><surname>Barney</surname><given-names>JA</given-names></name><name><surname>Uhrich</surname><given-names>TD</given-names></name><name><surname>Colinco</surname><given-names>MD</given-names></name></person-group><article-title>The effects of increasing plasma concentrations of dexmedetomidine in humans</article-title><source>Anesthesiology</source><year>2000</year><volume>93</volume><fpage>382</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">10910487</pub-id></element-citation></ref></ref-list></back></article>